- Friday, March 31, 2023
7:45 AM – 8:00 AM CT
Welcome
7:45 AM – 8:00 AM CT
WelcomeCo-Chair: – Vanderbilt-Ingram Cancer Center
Co-Chair: – University of Chicago
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Co-Chair###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Co-Chair: – Vanderbilt-Ingram Cancer Center
### @@@ Sonia Kupfer, MD (she/her/hers) – University of Chicago ### 1849665###Co-Chair###Associate Professor of Medicine###University of Chicago###Co-Chair: – University of Chicago
### she/her/hers8:00 AM – 8:15 AM CT
8 - Session 7: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided All RAS Wild-Type Metastatic Colorectal Cancer (mCRC) - Triplet Chemo + Bevacizumab
8:00 AM – 8:15 AM CT
Session 7: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided All RAS Wild-Type Metastatic Colorectal Cancer (mCRC) - Triplet Chemo + BevacizumabPresenter: – Fox Chase Cancer Center
Namrata (Neena) Vijayvergia, MD, FACP – Fox Chase Cancer Center ### 1544845###Presenter###Assistant Chief, Gastrointestinal Medical Oncology; Associate Professor###Fox Chase Cancer Center###Presenter: – Fox Chase Cancer Center
### 8:15 AM – 8:30 AM CT
9 - Session 7: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided all RAS Wild-Type Metastatic Colorectal Cancer (mCRC) - Doublet Chemo + Panitumumab
8:15 AM – 8:30 AM CT
Session 7: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided all RAS Wild-Type Metastatic Colorectal Cancer (mCRC) - Doublet Chemo + PanitumumabPresenter: – Department of Hematology and Oncology at Cleveland Clinic
Smitha Krishnamurthi, MD (she/her/hers) – Department of Hematology and Oncology at Cleveland Clinic ### 1691686###Presenter###Associate Professor###Department of Hematology and Oncology at Cleveland Clinic###Presenter: – Department of Hematology and Oncology at Cleveland Clinic
### she/her/hers8:30 AM – 8:45 AM CT
9 - Session 7: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided all RAS Wild-Type Metastatic Colorectal Cancer (mCRC) - Discussion
8:30 AM – 8:45 AM CT
Session 7: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided all RAS Wild-Type Metastatic Colorectal Cancer (mCRC) - DiscussionSession Moderator: – Vanderbilt-Ingram Cancer Center
Session Moderator: – University of Chicago
Panelist: – Fox Chase Cancer Center
Panelist: – Department of Hematology and Oncology at Cleveland Clinic
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Session Moderator###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Session Moderator: – Vanderbilt-Ingram Cancer Center
### @@@ Sonia Kupfer, MD (she/her/hers) – University of Chicago ### 1849665###Session Moderator###Associate Professor of Medicine###University of Chicago###Session Moderator: – University of Chicago
### she/her/hers @@@ Namrata (Neena) Vijayvergia, MD, FACP – Fox Chase Cancer Center ### 1544845###Panelist###Assistant Chief, Gastrointestinal Medical Oncology; Associate Professor###Fox Chase Cancer Center###Panelist: – Fox Chase Cancer Center
### @@@ Smitha Krishnamurthi, MD (she/her/hers) – Department of Hematology and Oncology at Cleveland Clinic ### 1691686###Panelist###Associate Professor###Department of Hematology and Oncology at Cleveland Clinic###Panelist: – Department of Hematology and Oncology at Cleveland Clinic
### she/her/hers8:45 AM – 9:30 AM CT
1 - Session 8: Emerging Treatment Strategies for HER2+ mCRC: Molecular Profiling and Targeted Therapies
8:45 AM – 9:30 AM CT
Session 8: Emerging Treatment Strategies for HER2+ mCRC: Molecular Profiling and Targeted TherapiesPresenter: – Duke University
John Strickler, MD (he/him/his) – Duke University ### 1422831###Presenter###Associate Professor###Duke University###Presenter: – Duke University
### he/him/his9:30 AM – 10:30 AM CT
Discover a Treatment Option for Locally Advanced or Metastatic Biliary Tract Cancer. Speaker: Dr. Chih-Yi “Andy” Liao
9:30 AM – 10:30 AM CT
Non-CME Innovation Theater (Sponsored by AstraZeneca)
10:30 AM – 10:45 AM CT
Exhibit Hall
10:30 AM – 10:45 AM CT
Exhibit Hall
10:45 AM – 11:30 AM CT
Session 9: Updates from Recent Meetings
10:45 AM – 11:30 AM CT
Session 9: Updates from Recent MeetingsPresenter: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Presenter###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Presenter: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### 11:30 AM – 11:45 AM CT
8 - Session 10: Debate: Pancreatic NETs: PRRT vs Chemotherapy - PRRT
11:30 AM – 11:45 AM CT
Session 10: Debate: Pancreatic NETs: PRRT vs Chemotherapy - PRRTPresenter: – The University of Texas MD Anderson Cancer Center
Arvind Dasari, MD – The University of Texas MD Anderson Cancer Center ### 1428669###Presenter###Associate Professor###The University of Texas MD Anderson Cancer Center###Presenter: – The University of Texas MD Anderson Cancer Center
### 11:45 AM – 12:00 PM CT
8 - Session 10: Debate: Pancreatic NETs: PRRT vs Chemotherapy - Chemotherapy
11:45 AM – 12:00 PM CT
Session 10: Debate: Pancreatic NETs: PRRT vs Chemotherapy - ChemotherapyPresenter: – Huntsman Cancer Institute at the University of Utah
Heloisa Soares, MD, PhD (she/her/hers) – Huntsman Cancer Institute at the University of Utah ### 1880692###Presenter###Associate Professor###Huntsman Cancer Institute at the University of Utah###Presenter: – Huntsman Cancer Institute at the University of Utah
### she/her/hers12:00 PM – 12:15 PM CT
8 - Session 10: Debate: Pancreatic NETs: PRRT vs Chemotherapy - Discussion
12:00 PM – 12:15 PM CT
Session 10: Debate: Pancreatic NETs: PRRT vs Chemotherapy - DiscussionSession Moderator: – Vanderbilt-Ingram Cancer Center
Session Moderator: – University of Chicago
Panelist: – The University of Texas MD Anderson Cancer Center
Panelist: – Huntsman Cancer Institute at the University of Utah
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Session Moderator###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Session Moderator: – Vanderbilt-Ingram Cancer Center
### @@@ Sonia Kupfer, MD (she/her/hers) – University of Chicago ### 1849665###Session Moderator###Associate Professor of Medicine###University of Chicago###Session Moderator: – University of Chicago
### she/her/hers @@@ Arvind Dasari, MD – The University of Texas MD Anderson Cancer Center ### 1428669###Panelist###Associate Professor###The University of Texas MD Anderson Cancer Center###Panelist: – The University of Texas MD Anderson Cancer Center
### @@@ Heloisa Soares, MD, PhD (she/her/hers) – Huntsman Cancer Institute at the University of Utah ### 1880692###Panelist###Associate Professor###Huntsman Cancer Institute at the University of Utah###Panelist: – Huntsman Cancer Institute at the University of Utah
### she/her/hers12:15 PM – 1:15 PM CT
Lunch
12:15 PM – 1:15 PM CT
Lunch
1:15 PM – 2:00 PM CT
Session 11: Advances in Neuroendocrine Tumors (NETs)
1:15 PM – 2:00 PM CT
Session 11: Advances in Neuroendocrine Tumors (NETs)Presenter: – The University of Texas MD Anderson Cancer Center
Arvind Dasari, MD – The University of Texas MD Anderson Cancer Center ### 1428669###Presenter###Associate Professor###The University of Texas MD Anderson Cancer Center###Presenter: – The University of Texas MD Anderson Cancer Center
### 2:00 PM – 2:15 PM CT
Session 12: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer - NALIRIFOX
2:00 PM – 2:15 PM CT
Session 12: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer - NALIRIFOXPresenter: – MD Anderson Cancer Center, The University of Texas
Milind M. Javle, MD – MD Anderson Cancer Center, The University of Texas ### 944699###Presenter###Professor of Medicine###MD Anderson Cancer Center, The University of Texas###Presenter: – MD Anderson Cancer Center, The University of Texas
### 2:15 PM – 2:30 PM CT
Session 12: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer - FOLFIRINOX
2:15 PM – 2:30 PM CT
Session 12: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer - FOLFIRINOXPresenter: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Presenter###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Presenter: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### 2:30 PM – 2:45 PM CT
Session 12: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer - Discussion
2:30 PM – 2:45 PM CT
Session 12: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer - DiscussionSession Moderator: – Vanderbilt-Ingram Cancer Center
Session Moderator: – University of Chicago
Panelist: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Panelist: – MD Anderson Cancer Center, The University of Texas
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Session Moderator###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Session Moderator: – Vanderbilt-Ingram Cancer Center
### @@@ Sonia Kupfer, MD (she/her/hers) – University of Chicago ### 1849665###Session Moderator###Associate Professor of Medicine###University of Chicago###Session Moderator: – University of Chicago
### she/her/hers @@@ Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Panelist###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Panelist: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### @@@ Milind M. Javle, MD – MD Anderson Cancer Center, The University of Texas ### 944699###Panelist###Professor of Medicine###MD Anderson Cancer Center, The University of Texas###Panelist: – MD Anderson Cancer Center, The University of Texas
### 2:45 PM – 3:15 PM CT
Exhibit Hall
2:45 PM – 3:15 PM CT
Exhibit Hall
3:15 PM – 4:00 PM CT
15 - Session 13: The Pillars of Cancer Wellness
3:15 PM – 4:00 PM CT
Session 13: The Pillars of Cancer WellnessPresenter: – Memorial Sloan Kettering Cancer Center
Gary E. Deng, MD, PhD – Memorial Sloan Kettering Cancer Center ### 1699641###Presenter###Medical Director, Integrative Medicine Service###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
### 4:00 PM – 4:45 PM CT
14 - Session 14: The Power of Patient Advocacy
4:00 PM – 4:45 PM CT
Session 14: The Power of Patient AdvocacyPresenter: – Fight Colorectal Cancer
Anjee Davis, MPPA (she/her/hers) – Fight Colorectal Cancer ### 1867780###Presenter###President###Fight Colorectal Cancer###Presenter: – Fight Colorectal Cancer
### she/her/hers
